Test of a new Lu-177-PSMA-based radio... - Advanced Prostate...

Advanced Prostate Cancer

20,781 members25,885 posts

Test of a new Lu-177-PSMA-based radiopharmaceutical at UCSF

Tall_Allen profile image
7 Replies

I know many patients are interested in trying a Lu-177-PSMA-based radiopharmaceutical without being randomized. UCSF will be starting a dose-finding (non randomized) trial of a new Lu-177-PSMA-based radiopharmaceutical . It is for those with mCRPC who have tried docetaxel (but not Jevtana), and have failed Zytiga or Xtandi. Here are the details:

clinicaltrials.gov/ct2/show...

In NYC, Scott Tagawa at Weill Cornell is testing the J591 ligand. There are similar requirements.

clinicaltrials.gov/ct2/show...

He is also testing a new Ac-225-PSMA-J591 radiopharmaceutical:

clinicaltrials.gov/ct2/show...

Written by
Tall_Allen profile image
Tall_Allen
To view profiles and participate in discussions please or .
Read more about...
7 Replies
dadeb profile image
dadeb

Happy to hear this. Wish we could have held on long enough - better to have skipped Radium 223 for this one.

Tall_Allen profile image
Tall_Allen in reply to dadeb

The exclusion is only 90 days for Xofigo. It's benefit is known. If you had bone mets only, Xofigo is a better bet.

dadeb profile image
dadeb in reply to Tall_Allen

Good to know. Thanks! No looking back.

CalBear74 profile image
CalBear74

You were kind enough to identify three options: the question is can the same patient qualify for all three and if so which would you suggest he choose for efficacy over the other two?

Tall_Allen profile image
Tall_Allen in reply to CalBear74

You can only do one because they preclude previous treatment by radiopharmaceuticals. These are ALL experimental and in Phase 1 trials, so I have no idea how safe or efficacious any of them are.

CalBear74 profile image
CalBear74 in reply to Tall_Allen

Assuming you could only do one, which one? And I guess you’re saying, we just don’t know yet which is the most efficacious? I was not suggesting that a patient could try and do more than one.

Tall_Allen profile image
Tall_Allen in reply to CalBear74

J591 MAY be more specific (less toxic) than PSMA-617. Ac-225 is more effective a short-range cancer killing; Lu-177 has a wider scope. I know nothing about the ligand that UCSF is using. That's all I can say.

You may also like...

New Phase 1b (NON-randomized, dose timing) trial of Lu-177-PSMA-617 + Keytruda at UCSF announced

men with mCRPC who are PSMA-avid (at least 3 PSMA-avid mets) and who have tried Zytiga, Xtandi or...

New Trial of Lu-177-PSMA-617 to begin April 30, 2021.

Novartis has announced a new multi-institutional randomized clinical trial of Lu-177-PSMA-617 that...

New randomized clinical trial of Lu-177-PSMA-617 for men who are still hormone sensitive

VISION trial. https://clinicaltrials.gov/ct2/show/NCT04720157 They had previously announced a new...

2nd LU 177 PSMA injection

I received my second LU 177 injection 2 days ago and feeling great so, far after having significant...

Lu 177 PSMA

for PSMA scan (I was) does this mean ALL of your prostate cancer cells will be positive for PSMA?...